Research
Hormonal
Patients treated with semaglutide experienced a greater improvement in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) compared to placebo, with an estimated treatment difference of 7.8 points (P < .001).
Semaglutide may be an effective treatment option for improving heart failure symptoms in obese patients.
StrongSupportsmedium confidence
At 52 weeks, the KCCQ-CSS improved from baseline in both groups, but to a greater extent in patients treated with semaglutide: 16.6 vs. 8.7 points [estimated treatment difference (ETD), 7.8 points; 95% confidence interval (CI), 4.8-10.9;P < .001].
Why this rating
The study is a large, double-blind, placebo-controlled trial.
Source
Moving a STEP forward in the treatment of patients with obesity and heart failure with preserved ejection fraction
Giovanna Liuzzo et al. · European Heart Journal · 2023
DOI 10.1093/eurheartj/ehad674
rct · n=529
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →